Press Release
Holistiplan, the Market Leader in Tax Planning Software, Unveils Tax Report 2.0 With Next-Level Visualizations and Enhanced Insights
Holistiplan's beloved Tax Report just got even better. Tax Report 2.0, powered by award-winning technology, introduces enhanced visuals and charts that simplify tax planning and provide clearer insights. This upgrade enables advisors and clients to plan taxes more effectively. Read More
Press Release
Ondas Receives $8.0 Million Purchase Order for Iron Drone Raider Systems from Major Military Customer for Aerial Protection Against Hostile Drones
Marks largest order ever for the Iron Drone Raider systems and a significant milestone in Ondas Autonomous Systems Inc (OAS) business unit's expansion Anticipating further growth with military and security customers worldwide, as Iron Drone's capabilities are utilized and demonstrated in live security operations through this purchase order Ondas believes the Iron Drone Raider system is one of the most innovative and promising technologies in the counter-drone market, featuring autonomous capabilities and cost-effective interception with minimal collateral damage Read More
Press Release
The Center for Immunology Science and Immunology Diagnostics Announce a Major Breakthrough Discovery: DNA-Based Proof of the Disease of Fibromyalgia
Groundbreaking Study Confirms Fibromyalgia as a True Medical Condition with 100% Accuracy Using Unique DNA Genomic Signatures, Offering New Hope for Objective Diagnosis and Treatment. Read More
Press Release
Registration Is Now Open For Tribe Public's Webinar Event "Diabetes, Obesity, GLP-1, & The MODD-1 Opportunity" Featuring Modular Medical CEO On Wednesday, September 11, 2024
Meet with Modular Medical CEO, Jeb Besser There are more than 3 million individuals who use daily insulin to help with the care of Diabetes in the US.100% of patient population require daily insulin injection. Only 20% currently use an insulin pump. Obesity is linked to 30% to 53% of new diabetes cases in the U.S. every year, per research in the Journal of the American Heart Association About half of all patients prescribed a GLP-1 drug for weight loss discontinued after the first 12 weeks, with approximately 30% discontinuing in the first four weeks Read More
Press Release